anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous studies demonstrated that pain scores upon local anesthetic injection is positively correlated to post-cesarean pain scores. Anxiety, anticipated post-operative pain score and anticipated medication need are also found to be promising risk factors to post-cesarean pain management.

The investigators would investigate the risk factors of causing post-cesarean emesis, and to reaffirm that there is a positive correlation between pain on local anesthetic injection, presence of mechanical temporal summation (MTS) and post-Cesarean pain scores. 470 parturients undergoing cesarean delivery and requiring regional anaesthesia will be recruited. Pain and anxiety assessment will be conducted via visual analogue scoring (VAS), MTS assessment and a series of questionnaires. After delivery, patients will be given appropriate analgesia, and pain score at movement will be recorded. Secondary outcomes include pain scores at rest, analgesia consumption, time-to-first-rescue analgesia, opioid-related side effects, patient satisfaction and postpartum depression. A separate 125 patients will be recruited to evaluate the feasibility and patient acceptability of the use of Headspace, a mindfulness mobile application during the pre- and postnatal period to improve the maternal outcomes (emesis, pain, anxiety, depression).
Participants completed a single session of exposure administered via a virtual reality headset. The exposure exercise involved looking over virtual railings into an atrium at various floor levels (the virtual environment was designed to look like the atrium in the in vivo exposure condition). Exposure was conducted in six 6-minute trials for a total of 36 minutes of exposure.
Fibrates increase the risk for myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal insufficiency, or hypothyroidism.

Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase (CPK) levels.

Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed.

Data from observational studies indicate that the risk for rhabdomyolysis is increased when fibrates, in particular gemfibrozil, are co-administered with a statin. The combination should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination [see Clinical Pharmacology (12.3)]. 

Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine [see Drug Interactions (7.4)].
All participants will have a refrigerated 0.09% cyclosporine drop instilled in one eye, and a non-refrigerated 0.09% cyclosporine drop instilled in the other eye. The eye that receives the refrigerated drop is randomly determined.
The invention discloses iridoids, and a preparation method and application thereof. The structural formula of the iridoids is disclosed as Figure 1. The preparation method comprises the following steps: leaching Gentiana triflora Pall. in an organic solvent to obtain a leaching solution; extracting the leaching solution, and concentrating the extracting solution to obtain an extract; and separating and purifying the iridoids from the extract. The iridoids are applicable to preparing anti-inflammatory agents. Compared with the prior art, the iridoids disclosed by the invention are new compounds having strong anti-inflammatory activity, and can be used for preparing anti-inflammatory agents.
Provides are approaches for anticancer and antiaging treatments by administration of reverse transcriptase (RT) activity inhibitors that function to inhibit RT encoded by ORF2 of LINE1, or any RT that can participate in transcriptional activation of retroelements. Also provided are approaches to discovery of new compounds that can inhibit RTs, and identifying individuals who would benefit from treatment with such RT inhibitors, and treating such individuals. The methods are applicable for use in populations of cancer cells, pre-cancerous cells, somatic cells, and combinations thereof. Also provided are methods for monitoring the efficacy of a treatment that inhibits development of resistance to pharmaceutical agents, methods for prophylaxis and/or therapy for a pathology correlated with accumulation of somatic cells capable of spontaneously generating genetic alterations independently of cell divisions, wherein such cells express functional LINE1 elements. Also provides are methods for treating and/or preventing age-related conditions in an individual by administering an agent capable of selectively killing the cells that exhibit genetic instability as evidenced by expression of functional LINE 1. Also provided are methods for sensitizing cancer cells to a chemotherapeutic agent by administering an RT inhibitor.
The subject invention provides compositions for promoting good health. Specifically, the subject composition can be used for alleviating symptoms of indigestion, abdominal pain, and cephalic syndrome, including in healthy subjects. In preferred embodiments, the compositions comprise an effective amount of one or more  Lactobacillus  isolates. Preferably, the bacteria used as an active ingredient in the compositions of the subject invention are of the  L. johnsonii  N6.2 strain. The subject invention also provides methods for alleviating symptoms of indigestion, abdominal pain, and cephalic syndrome. These methods comprise the administration of a composition of the subject invention, wherein the composition preferably comprises an effective amount of one or more  Lactobacillus  isolates. Even more preferably, the subject method utilizes an effective amount of  L. johnsonii  N6.2.
A surface envelope of silica over water droplets is formed by intensively shaking water and hydrophobic silica or by atomizing water and hydrophobic silica in a cyclone into which they are introduced through separate nozzles. The hydrophobic silica is made by contacting silica (of particle size 10-40 mm  and of B.E.T. surface about 150 m2/g and carbon content 1-1.5% by weight) with 0.75 m. mol. per gm. of silica of a haloalkyl silane, e.g. dimethyldichlorosilane as disclosed in Specification 1,031,764.  The water droplets can have a size of 2-3 x 10-2 mm.  The product is a white powder having a water to silica content of 5 to 10:1 parts by weight.  On freezing and thawing the product or under pressure the water separates from the silica.  The water in the product may be present in an aqueous solution, e.g. of pharmaceutical or cosmetic substances.  The product can be used as a fire-retardant.
The present utility model pertains to a composition of non-woven fabric (composed of micro- and nanofibers, known as “mat”). Said fabric contains some biocompatible and biodegradable cellulose ester and the polyphenolic compound rosmarinic acid which has strong antioxidant, antibacterial, antifungal and anti-inflammatory properties. The non-woven fabric is obtained by electrospinning from a solution of some cellulose ester (e.g. cellulose acetate) containing the polyphenolic compound rosmarinic acid as well as some non-ionogenic water-miscible polymer such as polyethylene glycol. The non-ionogenic water-miscible polymer improves the solubility of the polyphenolic compound in water and facilitates its release from the non-woven textile. The so-obtained non-woven fabric would be applied in biomedicine, in the textile industry, in the pharmaceutical industry and/or in cosmetic products for topical application, as well as for personal care, medicinal or dressing materials, for the making of disposable materials and so on.
BACKGROUND: Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. This study aimed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, on the obese- and diabetes-related cardiomyopathy.
METHODS AND RESULTS: We used db/db mice and high fat diet-streptozotocin induced diabetic mice to investigate the underlying mechanisms of fenofibrate's beneficial effects on heart function. Fenofibrate reduced fibrosis, and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. The Korean National Health Insurance database was used to identify 427,154 fenofibrate users and 427,154 non-users for comparison. During the 4.22-year follow-up, fenofibrate use significantly reduced the risk of HF hospitalization (hazard ratio, 0.907; 95% CI 0.824-0.998).
CONCLUSIONS: The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.
The adrenal glands sit above the kidneys and are part of the body's endocrine system. They produce a number of different steroid hormones; those involved in metabolism (glucocorticoids, principally cortisol and its more inactive form, cortisone), salt and water balance (aldosterone) and sex steroids (oestrogen and testosterone). Measurement of steroids, in particular glucocorticoids, in saliva rather than blood samples, is gaining popularity as it offers a non-invasive collection technique, enabling sampling in outpatients, the community or the home environment, and therefore an improved patient experience.

Adrenal insufficiency (AI) describes the inability of the body to produce adequate levels of the vital stress hormone, cortisol. It is associated with considerable mortality and morbidity. There are numerous causes, both in adults and children. The commonest cause in children is AI secondary to steroid medication prescribed for inflammatory conditions such as arthritis and asthma. AI is usually permanent but, especially in those patients taking steroid medication, it may not be, and repeated testing may be required. Testing for AI requires measurement of cortisol. Cortisol levels change during the day (highest soon after waking) and increase in response to stress. There is a lack of data on what constitutes a normal cortisol level under different conditions in children, especially babies and very young children. The investigators would like to use salivary glucocorticoid sampling to study normal responses in children, in order to be able to better define what is abnormal, to ensure appropriate and safe management of children at risk of AI in the future. The current salivary collection techniques (SCT) require active patient participation, present a potential choking hazard, and are therefore unsuitable for very young children. The investigators have been working on a SCT suitable for neonates, infants, and toddlers. Our novel SCT uses a salivary steroid swab encased in a pacifier/dummy (SaliPac) and will enable study of normal adrenal gland function at different ages and under different conditions and disease states from which the investigators will construct normal reference ranges. The final step in the validation of the novel SCT is this patient study where usability, patient tolerability and carer acceptability will be examined.
Rice (Oryza sativa L.) grown in many countries around the world with different climatic conditions and a huge number of environmental stresses, both biotic (fungi, bacteria, viruses, insects) and abiotic (cold, drought, salinity) limit rice productivity. In this regard, breeders and scientists are trying to create rice lines that are resistant to multiple stresses. The aim of this work was to screen and select cold and blast resistant rice breeding lines (RBLs) using molecular markers. Molecular screening of RBLs and parental varieties to cold tolerance was carried out using markers RM24545, RM1377, RM231 and RM569 associated with QTLs (qPSST-3, qPSST-7, qPSST-9). It was discovered that the presence of three QTLs characterizes the cold resistance of studied genotypes, and the absence of one of them leads to cold sensitivity. As a result, 21 cold-resistant out of the 28 studied RBLs were identified. These cold resistant 21 RBLs were further tested to blast resistance using markers Pi-ta, Pita3, Z56592, 195R-1, NMSMPi9-1, TRS26, Pikh MAS, MSM6, 9871.T7E2b, RM224 and RM1233. It was revealed that 16 RBLs from 21 studied lines contain 5-6 blast resistance genes. In accordance with the blast resistance strategy, the presence of 5 or more genes ensures the formation of stable resistance to Magnaporthe oryzae. Thus, 16 lines resistant to multiple stresses, such as cold and blast disease were developed. It should be noted that 6 of these selected lines are high-yielding, which is very important in rice breeding program. These RBLs can be used in breeding process as starting lines, germplasm exchange as a source of resistant genes for the development of new rice varieties resistant to multiple stress factors.
PURPOSE:To obtain an emulsion compsn. excellent in the feeling of use and in emulsion stability and suitable for cosmetics, a base material of a medicine, etc., by emulsifying organopolysiloxanes, polyoxyalkylene-modified organopolysiloxane, and an ionic surfactant in water. CONSTITUTION:The compsn. is prepd. by emulsifying, in water, an organopolysiloxane of the formula (wherein R is a 1-6C monovalent hydrocarbon group; and n is, on an average, 500-10,000) (A), an organopolysiloxane having a viscosity index at 25 deg.C of 1-500cSt (B1), a polyoxyalkylene-modified organopolysiloxane having an HLB value of 5-12 (C), and an ionic surfactant (D) in a wt. ratio of the sum of components A and B to the sum of components C and D of (95:5)-(50:50) and in a wt. ratio of component D to the sum of components C and D of 0.5-20wt.%.
Patients receive an SGLT2i medication, such as dapagliflozin, empagliflozin, or canagliflozin. These drugs work by preventing the kidneys from reabsorbing glucose from the urine, leading to lower blood sugar levels and potentially reducing the risk of kidney damage.
OBJECTIVES: Aortic valved allografts (homografts) have been used alternatively to mechanical or biological valve prostheses in expectation of better durability; however, homograft valves do degenerate, and redo procedures have proven challenging due to heavy wall calcification. The aim of the study was to compare the outcome of open surgical (SAVR) and transcatheter aortic valve replacement (TAVR) in degenerated homografts.
METHODS: Between 1993 and 2022, 81 patients underwent repeat aortic valve procedures having previously received an aortic homograft. The redo had become necessary due to regurgitation in 85% and stenosis in 15%. Sixty-five percent underwent open surgery, 35% TAVR.
RESULTS: Isolated SAVR was possible in 79%, and root procedures were necessary in 21%. TAVR was performed in 79% via transfemoral and 21% via transapical access. Median prosthetic valve size was 23 (22.3-23.2) mm in the SAVR and 26 (25.2-26.9) in the TAVR group. Thirty-day mortality was 0% in the TAVR and 7% in the SAVR group (P = n.s.). TAVR showed a significantly better outcome concerning prolonged ventilation (0 vs 21%, P = 0.013) as well as ICU (1 vs 2 days; P < 0.001) and in-hospital stay (10.5 vs 13 days; P = 0.028). Five-year survival was statistically comparable between groups, and no severe leakage was observed.
CONCLUSIONS: SAVR following structural homograft degeneration shows acceptable results, but the perioperative risk remains substantial and poorly predictable. TAVR presents a reasonable and more easily accessible alternative and is associated with good short- and mid-term results. In the absence of relevant contraindications, TAVR is presently the preferred treatment option for these patients at our center.
Participants randomized to the TAU condition will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions) for a 16-week period. Treatment changes (e.g., medication increase, starting psychotherapy in community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
BACKGROUND: People with vision impairment encounter many difficulties when it comes to medicines use. However, evidence indicates that there are major gaps in pharmaceutical care service provision worldwide and limited research on interventions to optimise medication use for this patient population. The Theoretical Domains Framework (TDF) provides a method for theoretically understanding individuals' behaviour and informing development of interventions. The aim of this research was to (a) identify the barriers and facilitators to the provision of medication dispensing and counselling services by pharmacists to patients with vision impairment, and (b) identify key TDF domains to be targeted in a future intervention.
METHODS: Semi-structured interviews were conducted with pharmacists from different pharmacy practice settings/areas in Saudi Arabia. The 14-domain TDF was utilised as the theoretical lens through which pharmacists' behaviours were examined. Interviews were conducted in Arabic or English, either face-to-face or over the telephone based on the participant's preference. Following transcription, interviews conducted in Arabic were translated into English before analysis. Data analysis involved using the framework method and content analysis to identify important barriers and facilitators to the provision of dispensing and counselling services to those with vision impairment. Key TDF domains that could be targeted in a future intervention were then identified using a consensus-based approach.
RESULTS: Twenty-six pharmacists were interviewed. Pharmacists' experience in pharmacy practice ranged from two to 28 years. A range of barriers and facilitators were highlighted as important in providing services to those with vision impairment. Eight domains were identified as 'key domains' including: 'Knowledge', 'Skills', 'Beliefs about capabilities', 'Goals', 'Memory, attention, and decision processes', 'Environmental context and resources', 'Social influences', and 'Behavioural regulation'.
CONCLUSIONS: Barriers and facilitators identified by pharmacists will inform the development of an intervention to ensure its applicability to everyday practice. Future research will focus on the process of developing the proposed intervention through targeting key TDF domains to improve medication dispensing and counselling by pharmacists to patients with vision impairment.
NEW MATERIAL:Indole compounds such as 7-(2-hydroxy-3-isopropylamino) propoxyindole or derivative thereof of formula I [R is (2-hydroxy-3- isopropylamino)propoxy; R1 is H or protective group]. EXAMPLE:2,3-Dihydro-7-(2-hydroxy-3-isopropylamino)propoxyindole. USE:Having excellent beta-sympatholytic action and useful for remedy of hypertension as an antihypertensive agent. PREPARATION:2,3-Dihydro-7-hydroxyindole derivative of formula II (R1 is protective group) is used as the raw material and epichlorohydrin is reacted therewith to prepare 2,3-dihydro-7-(2,3-epoxy)propoxyindole derivative of formula III. Isopropylamine is then reacted therewith and the protective group is removed for substitution by hydrogen as necessary. A dehydrogenation reaction is subsequently carried out, thus obtaining the objective compound of formula I.
BACKGROUND: Non-communicable diseases (NCDs) cause long-term impacts on health and can substantially affect people's ability to work. Little is known about how such impacts vary by gender, particularly in low- and middle-income countries (LMICs), where productivity losses may affect economic development. This study assessed the long-term productivity loss caused by major NCDs among adult women and men (20-76 years) in Mexico because of premature death and hospitalisations, between 2005 and 2021.
METHODS: We conducted an economic valuation based on the Human Capital Approach. We obtained population-based data from the National Employment Survey from 2005 to 2021 to estimate the expected productivity according to age and gender using a two-part model. We utilised expected productivity based on wage rates to calculate the productivity loss, employing Mexican official mortality registries and hospital discharge microdata for the same period. To assess the variability in our estimations, we performed sensitivity analyses under two different scenarios.
RESULTS: Premature mortality by cancers, diabetes, chronic cardiovascular diseases (CVD), chronic respiratory diseases (CRD) and chronic kidney disease (CKD) caused a productivity loss of 102.6 billion international US dollars (Intl. USD) from 2.8 million premature deaths. Seventy-three percent of this productivity loss was observed among men. Cancers caused 38.3% of the productivity loss (mainly among women), diabetes 38.1, CVD 15.1, CRD 3.2, and CKD 5.3%. Regarding hospitalisations, the estimated productivity loss was 729.7 million Intl. USD from 54.2 million days of hospitalisation. Men faced 65.4 and women 34.6% of these costs. Cancers caused 41.3% of the productivity loss mainly by women, followed by diabetes (22.1%), CKD (20.4%), CVD (13.6%) and CRD (2.6%).
CONCLUSIONS: Major NCDs impose substantial costs from lost productivity in Mexico and these tend to be higher amongst men, while for some diseases the economic burden is higher for women. This should be considered to inform policymakers to design effective gender-sensitive health and social protection interventions to tackle the burden of NCDs.
Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.